Neurocrine Stock Falls On Unusually High Volume (NBIX)

NEW YORK (TheStreet) -- Neurocrine Biosciences (Nasdaq:NBIX) is trading at unusually high volume Thursday with 1.5 million shares changing hands. It is currently at four times its average daily volume and trading down 72 cents (-7.7%) at $8.64 as of 2:15 p.m. ET.

Neurocrine has a market cap of $447.6 million and is part of the health care sector and drugs industry. Shares are up 10.2% year to date as of the close of trading on Wednesday.

Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company has a P/E ratio of 13.7, above the average drugs industry P/E ratio of 11.6 and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Neurocrine as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall. You can view the full Neurocrine Ratings Report.

See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.

Interested in other stocks that are falling on unusually high volume? Get free SMS text alerts sent to you when the action happens by texting HVDOWN to 95370 or select from multiple alert options.

For more information on Neurocrine Biosciences Inc. click any of the following:

• Neurocrine Biosciences Inc. Stock Price

• Neurocrine Biosciences Inc. Analyst Ratings

• Neurocrine Biosciences Inc. Key Stats & Profile

• Neurocrine Biosciences Inc. Earnings

• Neurocrine Biosciences Inc. Ratio Comparison

• Neurocrine Biosciences Inc. Growth Rates

• Neurocrine Biosciences Inc. Balance Sheet

• Neurocrine Biosciences Inc. Cash Flow

• Neurocrine Biosciences Inc. Income Statement